Mersey 1984.

Methods	Minimum 2‐week washout period; 3‐week single‐blind placebo lead‐in period; inclusion criteria=supine DBP 95‐114 mm Hg; 7‐week double‐blind treatment, consisting of 3‐week dose titration period (initial dose of 1 mg once daily, increased by steps to 20 mg once daily, regardless of BP) followed by 4‐week fixed dose period
Participants	Reported in Mersey 1984: All patients: n=64(41 males, 23 females); 35 white, 29 other; age range 21‐72 years; Terazosin 20 mg: n=38; baseline supine SBP=149.7 mm Hg, DBP=100.4 mm Hg Placebo: n=26; baseline supine SBP=147.1 mm Hg, DBP=99.2 mm Hg Reported in Dauer 1986 (Study M81‐061): Terazosin 20 mg: n=38; baseline standing SBP=147.9(15.4) mm Hg, DBP=103.3(6.2) mm Hg; baseline supine SBP=152.2(13.6) mm Hg, DBP=101.0(3.7) mm Hg Placebo: n=26; baseline standing SBP=143.8(15.3) mm Hg, DBP=100.4(6.1) mm Hg; baseline supine SBP=147.1(13.8) mm Hg, DBP=99.2(3.6) mm Hg
Interventions	Terazosin 20 mg once daily Placebo
Outcomes	Reported in Mersey 1984: Change from baseline in trough supine SBP/DBP using mercury sphygmomanometer Change from baseline in peak supine SBP/DBP using mercury sphygmomanometer Reported in Dauer 1986 (Study M81‐061): Change from baseline in trough standing SBP/DBP using mercury sphygmomanometer Change from baseline in trough supine SBP/DBP using mercury sphygmomanometer
Notes	Used BP data reported in Dauer 1986 instead of Mersey 1984 Reported in Mersey 1984: BP change reported, SD of change not reported, endpoint BP reported, endpoint SD not reported; baseline BP reported, baseline SD not reported Reported in Dauer 1986 (Study M81‐061): BP change and SE of change reported, endpoint BP and SD not reported; baseline BP and SE reported; calculated SD of change from N and SE of change; BP data from Table IV, p. 32
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	High risk	Losses to follow‐up and withdrawals not reported in Mersey 1984 or separately for M81‐061 in Dauer 1986. Unclear how dropouts were dealt with.
Selective reporting (reporting bias)	High risk	BP lowering efficacy was primary outcome. Quote: "...pulse rate did not increase with P or T." Comment: Quantitative HR and safety/tolerability not reported in abstract or separately for Study M81‐059 in Dauer 1986.
Other bias	High risk	Full trial data has not been published separately, only summarized in abstract and Dauer 1986 review article. Funding source not reported.